Propanc Biopharma (PPCB) Current Deferred Tax Assets (2017 - 2018)
Propanc Biopharma (PPCB) posted quarterly Current Deferred Tax Assets of $56413.0 for Q2 2018, up 26.07% year-over-year from $44749.0 in Q2 2017, and up 26.07% quarter-over-quarter from $44749.0 in Q2 2017.
Propanc Biopharma (PPCB) Current Deferred Tax Assets (2017 - 2018) Analysis & Trends
Propanc Biopharma (PPCB) has reported Current Deferred Tax Assets for 2 consecutive years, with $56413.0 the latest figure, recorded in Q2 2018.
- In Q2 2018, Current Deferred Tax Assets rose 26.07% year-over-year to $56413.0; the TTM figure through Jun 2018 stood at $56413.0 (up 26.07% YoY), while the FY2018 annual figure was $56413.0, up 26.07% from the prior year.
- Current Deferred Tax Assets grew to $56413.0 in Q2 2018 per PPCB's latest filing, from $44749.0 in the prior quarter.
- Across five years, Current Deferred Tax Assets topped out at $56413.0 in Q2 2018 and bottomed at $44749.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 56,413.00 |
| Jun 30, 2018 | 56,413.00 |
| Jun 30, 2017 | 44,749.00 |
| Jun 30, 2017 | 44,749.00 |